Virulence factors and genetic variability of vaginal Candida albicans isolates from HIV-infected women in the post-highly active antiretroviral era

AUTOR(ES)

Zanni, Pâmela Cristina Mastellaro Delvas, Bonfim-Mendonça, Patrícia de Souza, Negri, Melyssa, Nakamura, Sandra Sayuri, Donatti, Lucélia, Svidzinski, Terezinha Inez Estivalet, Consolaro, Márcia Edilaine Lopes

FONTE

Rev. Inst. Med. trop. S. Paulo

DATA DE PUBLICAÇÃO

03/08/2017

RESUMO

ABSTRACT Vulvovaginal candidiasis (VVC) in HIV-infected (HIV+) women is a serious public health problem. However, little is known about the virulence mechanisms of vaginal Candida albicans from HIV+ women in the post-highly active antiretroviral therapy (HAART) era. Here, we report a comparative analysis of the expression of key virulence factors and genetic variability of 26 vaginal C. albicans strains isolated from HIV+ women undergoing HAART and 18 from HIV-uninfected (HIV-) women. In general, we observed that C. albicans from HIV+ women receiving HAART showed lower expression of virulence factors compared with C. albicans from HIV- women, except for the proteinase activity which is highly expressed. The results in HIV-women further suggest that virulence factors appear to be expressed in response to the yeast stress, in the presence of an adequate immune response. Furthermore, the RAPD results showed a high heterogeneity among isolates from both groups of women. These findings in HIV+ women using HAART will help to improve the monitoring of vaginal yeast infections and the quality of life of patients.

Documentos Relacionados

• Survival of HIV‐infected patients in the intensive care unit in the era of highly active antiretroviral therapy
• Candida species isolated from the vaginal mucosa of HIV-infected women in Salvador, Bahia, Brazil
• Occurrence of pneumocystis pneumonia in hiv-infected patients and the interference of the highly active antiretroviral therapy
• Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factors
• Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy